Current Edition

Upcoming Events

Advertisement

news

FDA approves new Bristol Myers drug for lung cancer

Dive Brief: The Food and Drug Administration on Wednesday approved Bristol Myers Squibb’s new lung cancer medication Augtyro, which the drugmaker believes will b...
Continue Reading →
news

Top FDA official Woodcock to retire early next year

Janet Woodcock, a top Food and Drug Administration official who had been on the short list to head the agency under President Joe Biden, will retire in early 2024 af...
Continue Reading →
news

Lilly weight loss drug approved by FDA

The Food and Drug Administration on Wednesday approved a powerful new medicine for weight loss, clearing Eli Lilly’s Zepbound for adults with obesity or who are over...
Continue Reading →
news

Biogen says growth is coming, but won’t specify when

For the first time in more than three years, Biogen is reporting an annual increase in quarterly revenue. In earnings released Wednesday, the Cambridge, Massachus...
Continue Reading →
news

Bayer’s new CEO signals business shake-up, plans to slash management

New Bayer CEO Bill Anderson is promising a full-scale makeover of the 160-year-old German conglomerate, sharing his frustration with the company’s performance in a r...
Continue Reading →
news

Biogen, Sage set price of postpartum depression pill at $15,900

Dive Brief: Biogen and Sage Therapeutics will charge a sticker price of nearly $16,000 for a two-week course of their new postpartum depression drug Zurzuvae, th...
Continue Reading →
news

Moderna adjusts to changing outlook for COVID vaccine demand

Dive Brief: Moderna on Thursday shifted its revenue forecast for the year to “at least” $6 billion from a previous range of between $6 billion to $8 billion, a c...
Continue Reading →
news

Novartis bet on kidney disease drug yields positive study data

Dive Brief: An experimental kidney disease drug Novartis acquired via a $3 billion deal earlier this year succeeded in a late-stage trial, the Swiss pharmaceutic...
Continue Reading →
news

Sarepta gene therapy for Duchenne misses main goal of key study

A high-profile clinical trial testing Sarepta Therapeutics’ new gene therapy for Duchenne muscular dystrophy failed to meet its main goal, the biotechnology company ...
Continue Reading →
news

November brings new flurry of biotech layoffs

Biotechnology companies continue to contend with a challenging financial outlook, with at least four publicly traded drugmakers announcing layoffs to start November ...
Continue Reading →